Back to News
Market Impact: 0.2
Guggenheim Upgrades Editas Medicine to Buy from Neutral
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Guggenheim upgraded Editas Medicine (NASDAQGS: EDIT) to Buy from Neutral on September 23, 2026. The rating change is a positive catalyst for the gene-editing biotechnology company, though the article provides no price target, financial estimates, or clinical-program details to quantify the underlying rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EDIT0.55
More News
- Guggenheim upgrades Editas Medicine stock rating on gene editing therapy
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- US aviation sanctions disrupt Iran flights, push travellers overland
- Australia says OpenAI agent hacked Medicare portal
- Meta's standoff with Amazon over Muse could be a sign of things to come
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)